# Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

> **NCT02875613** · PHASE2 · TERMINATED · sponsor: **Assuntina Sacco, M.D.** · enrollment: 6 (actual)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT02875613
- **Lead sponsor:** Assuntina Sacco, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2018-04
- **Final completion:** 2019-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow patient accrual
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02875613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02875613, "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02875613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*